National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers Journal Article
| Authors: | Sturgeon, C. M.; Duffy, M. J.; Stenman, U. H.; Lilja, H.; Brünner, N.; Chan, D. W.; Babaian, R.; Bast, R. C. Jr; Dowell, B.; Esteva, F. J.; Haglund, C.; Harbeck, N.; Hayes, D. F.; Holten-Andersen, M.; Klee, G. G.; Lamerz, R.; Looijenga, L. H.; Molina, R.; Nielsen, H. J.; Rittenhouse, H.; Semjonow, A.; Shih, I. M.; Sibley, P.; Sölétormos, G.; Stephan, C.; Sokoll, L.; Hoffman, B. R.; Diamandis, E. P. |
| Article Title: | National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers |
| Abstract: | BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. METHODS: Published reports relevant to use of tumor markers for 5 cancer sites - testicular, prostate, colorectal, breast, and ovarian - were critically reviewed. RESULTS: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node-negative patients. CA15-3/BR27-29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers. © 2008 American Association for Clinical Chemistry. |
| Keywords: | mitogen activated protein kinase; treatment response; review; cancer recurrence; advanced cancer; cancer patient; cancer staging; colorectal cancer; ovarian neoplasms; prostate specific antigen; stem cell factor; unindexed drug; ovary cancer; breast cancer; differential diagnosis; carcinoembryonic antigen; epidermal growth factor receptor 2; tumor markers, biological; cancer screening; breast neoplasms; tumor marker; docetaxel; cancer hormone therapy; prostate cancer; colorectal neoplasms; prostatic neoplasms; early diagnosis; reference values; testicular neoplasms; interleukin 6; malignant neoplastic disease; lactate dehydrogenase; benign tumor; ca 125 antigen; estrogen receptor; progesterone receptor; trastuzumab; testis cancer; postmenopause; germ cell tumor; clinical laboratory; octamer transcription factor 4; seminoma; occult blood; plasminogen activator inhibitor 1; chorionic gonadotropin beta subunit; alpha fetoprotein; chorionic gonadotropin; urokinase; cd30 antigen; laboratory techniques and procedures; neuron specific enolase; alkaline phosphatase placenta isoenzyme; inhibin; protein kinase b beta; transvaginal echography; osteopontin; hla g antigen; pregnancy specific beta1 glycoprotein; ca 15-3 antigen; prostasin |
| Journal Title: | Clinical Chemistry |
| Volume: | 54 |
| Issue: | 12 |
| ISSN: | 0009-9147 |
| Publisher: | American Association for Clinical Chemistry |
| Date Published: | 2008-12-01 |
| Start Page: | e11 |
| End Page: | e79 |
| Language: | English |
| DOI: | 10.1373/clinchem.2008.105601 |
| PUBMED: | 19042984 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 73" - "Export Date: 17 November 2011" - "CODEN: CLCHA" - "Source: Scopus" |
